Compare Emerson Electric Co. (EMR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Regeneron Pharmaceuticals Inc — how do they compare? Emerson Electric Co. trades at $163.98 (market cap $88.53B), while Regeneron Pharmaceuticals Inc trades at $796.39 (market cap $83.19B). The key difference: Emerson Electric Co. and Regeneron Pharmaceuticals Inc are close in size by market cap, and Emerson Electric Co. pays the higher dividend (1.4%). Which is the better fit depends on your goals.
| EMR | REGN | |
|---|---|---|
Market Cap | $88.53B | $83.19B |
Sector | Industrials | Health |
52-Week High | $164.38 | $812.27 |
52-Week Low | $123.30 | $555.51 |
Enterprise Value | $99.60B | $77.90B |
Dividend Yield | 1.4% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $158.26, up 0.86% on the day, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows robust fundamentals, including a 13.83% net income margin and consistent revenue growth, supported by recent acquisitions like Glue Inc. to enhance AI capabilities. Analyst consensus is positive, with a $171.33 price target indicating potential upside from current levels.
Outlook remains favorable due to organic growth and raised 2026 guidance, but risks include valuation concerns with a P/E of 34.63 and macroeconomic pressures. Investment opportunity hinges on execution in automation and AI segments, while investors should monitor debt levels and competitive dynamics in the industrial sector.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
